By Colin Kellaher
Jupiter Neurosciences Inc. on Tuesday filed with the U.S. Securities and Exchange Commission for an initial public offering.
The filing by the Jupiter, Fla., clinical-stage pharmaceutical company indicates that it plans to raise up to $23 million through the sale of common stock and warrants, although that figure is often used as a placeholder to calculate filing fees.
Jupiter, which has developed a resveratrol platform product targeting treatment of neuro-inflammation, said it will apply to list its shares on the Nasdaq Capital Market under the symbol JUNS.
Write to Colin Kellaher at colin.kellaher@wsj.com